Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 2Phase 3 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 10Unknown 2Terminated 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2

Interventions

Metformin 16Cyclophosphamide 15Drug Therapy 14Dexamethasone 14Cisplatin 14Cytarabine 11Gemcitabine 10Radiotherapy 9Carboplatin 9Vincristine 8Paclitaxel 8Oxaliplatin 8Idarubicin 8Etoposide 8Docetaxel 8ulipristal acetate 7icotinib 7Sodium Chloride 7Methotrexate 7Fluorouracil 7Dexmedetomidine 7entecavir 6Thalidomide 6Surgical Procedures, Operative 6Sorafenib 6Pemetrexed 6Leuprolide 6Granulocyte Colony-Stimulating Factor 6Epirubicin 6Doxorubicin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Unknown × nilotinib × Clear all
NCT02602314 2022-01-20

SUSTRENIM

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 4 Unknown
450 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02389920 2015-03-17

Multicenter, Phaseâ…£, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib

Samsung Medical Center

Phase 4 Unknown
40 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡